Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide.

@article{Klasa2000EradicationOH,
  title={Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide.},
  author={Richard J Klasa and Marcel Bally and R Ng and James H. Goldie and Randy D. Gascoyne and F M Wong},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2000},
  volume={6 6},
  pages={2492-500}
}
Cancers overexpressing Bcl-2 protein, which prevents programmed cell death (apoptosis), are less sensitive to stresses that produce cellular damage, including chemotherapy. If the level of Bcl-2 protein can be reduced sufficiently using antisense oligonucleotides (ASOs) targeting the gene message, then cytotoxic agents may be rendered more effective in eliminating disease and increasing cure rate. Preclinical studies in SCID mice bearing Bcl-2 overexpressing systemic human B-cell lymphoma… CONTINUE READING